CABA-201

Phase 2Cell therapy

CCabaletta Bio

CABA-201 is one of 93 biologic programs targeting Generalized Myasthenia Gravis (gMG). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Generalized Myasthenia Gravis (gmg)Recruiting

Systemic Lupus ErythematosusRecruiting

Pemphigus VulgarisRecruiting

Systemic SclerosisRecruiting

Generalized Myasthenia Gravis (gmg)Preclinical

Recruiting

Systemic Lupus ErythematosusPhase 2

Recruiting

Pemphigus VulgarisPhase 2

Recruiting

Systemic SclerosisPhase 2

Recruiting

Competition

Competitive Landscape

134 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

9 2

Medrol

Pfizer

Phase 3

5 3

Rinvoq

AbbVie

Phase 3

3 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

12 5

Gazyva

Roche

Phase 3

2 6

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

3 7

Rapamune

PPrism Pharmaceuticals

Phase 3

1 8

Ianalumab

Novartis

Phase 3

3 9

Glucocorticoid

AbbVie

Phase 3

1 10

Telitacicept

VVor Biopharma

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1/2Recruiting

Pemphigus Vulgaris

NCT04422912

Q3 2029

PreclinicalRecruiting

Systemic Sclerosis

NCT06328777

PreclinicalRecruiting

Generalized Myasthenia Gravis (gmg)

NCT06359041

Q4 2029

PreclinicalRecruiting

Systemic Lupus Erythematosus

NCT06121297

Clinical

Trials by Indication[1]

Pemphigus Vulgaris1 trial

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Recruiting·CCabaletta Bio·Phase 1/2·NCT04422912·40 enrolled

Systemic Lupus Erythematosus1 trial

A Phase 1/2, Open-label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Systemic Lupus Erythematosus

Recruiting·CCabaletta Bio·Preclinical·NCT06121297·28 enrolled

Systemic Sclerosis1 trial

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Systemic Sclerosis

Recruiting·CCabaletta Bio·Preclinical·NCT06328777·37 enrolled

Generalized Myasthenia Gravis (gMG)1 trial

RESET-MG: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Generalized Myasthenia Gravis

Recruiting·CCabaletta Bio·Preclinical·NCT06359041·24 enrolled

Relapsing Multiple Sclerosis1 trial

RESET-MS: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Multiple Sclerosis

Withdrawn·CCabaletta Bio·Preclinical·NCT07006805

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for CABA-201. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CABA-201 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CABA-201. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cabaletta Bio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: CCabaletta Bio

CABA-201

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q3 2029

Q4 2029

Trials by Indication[1]

Pemphigus Vulgaris1 trial

Systemic Lupus Erythematosus1 trial

Systemic Sclerosis1 trial

Generalized Myasthenia Gravis (gMG)1 trial

Relapsing Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News